Drug Trial Radar · NCT06627647
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,160
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Nov 18, 2030
Study completion Nov 18, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
Conditions
- Non-squamous Non-small Cell Lung Cancer
Interventions
RilvegostomigDrug
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
PembrolizumabDrug
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
CarboplatinDrug
Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
CisplatinDrug
Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
PemetrexedDrug
Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to approximately 6 years
- Progression-free survival (PFS)Time frame: Up to approximately 6 years
Locations
301 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama · Recruiting
Research Site
Chandler, Arizona · Withdrawn
Research Site
Phoenix, Arizona · Recruiting
Research Site
Anaheim, California · Recruiting
Research Site
Beverly Hills, California · Recruiting
Research Site
Loma Linda, California · Recruiting
Research Site
Redlands, California · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Santa Rosa, California · Recruiting
Research Site
Walnut Creek, California · Recruiting
Research Site
Lone Tree, Colorado · Recruiting
Research Site
Stamford, Connecticut · Recruiting
Research Site
West Haven, Connecticut · Recruiting
Research Site
Newark, Delaware · Recruiting
Research Site
Bay Pines, Florida · Recruiting
Research Site
Fort Lauderdale, Florida · Recruiting
Research Site
Gainesville, Florida · Withdrawn
Research Site
Jacksonville, Florida · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Ocala, Florida · Recruiting
Research Site
St. Petersburg, Florida · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Boise, Idaho · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Decatur, Illinois · Recruiting
Research Site
Hinsdale, Illinois · Recruiting
Research Site
Quincy, Illinois · Recruiting
Research Site
Rockford, Illinois · Withdrawn
Research Site
Waterloo, Iowa · Recruiting
Research Site
Lexington, Kentucky · Recruiting
Research Site
Lexington, Kentucky · Withdrawn
Research Site
Louisville, Kentucky · Recruiting
Research Site
Alexandria, Louisiana · Withdrawn
Research Site
Baton Rouge, Louisiana · Recruiting
Research Site
Shreveport, Louisiana · Recruiting
Research Site
Shreveport, Louisiana · Recruiting
Research Site
South Portland, Maine · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Bethesda, Maryland · Not yet recruiting
Showing 40 of 301 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.